Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom

"Don't sell if prices don't drop!" Trump enforces a mandatory minimum drug price for developed countries, but a lawsuit battle may be "reenacted".

① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.

cls.cnMay 12 20:52 ET

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

BenzingaMay 12 19:00 ET

The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.

① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.

cls.cnMay 12 12:33 ET

Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress

BenzingaMay 12 07:20 ET

United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.

BenzingaMay 12 06:13 ET

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'

BenzingaMay 11 22:19 ET

8 Analysts Have This To Say About Natera

BenzingaMay 9 10:01 ET

Natera Analyst Ratings

BenzingaMay 9 09:50 ET · Ratings

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today

BenzingaMay 8 18:30 ET

Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.

BenzingaMay 8 16:30 ET

Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M

Seeking AlphaMay 8 16:16 ET

Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich

BenzingaMay 8 10:33 ET

Here Are the Major Earnings After the Close Today

Seeking AlphaMay 8 10:00 ET

Preview: Natera's Earnings

BenzingaMay 7 10:01 ET

Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming Dd-cfDNA Percentage Alone, AJT Publication Shows

BenzingaMay 7 07:15 ET

Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

BenzingaMay 6 13:24 ET · Ratings

Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165

BenzingaMay 6 10:08 ET · Ratings

FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday

BenzingaMay 6 10:02 ET

Neurocrine Biosciences Analyst Ratings

BenzingaMay 6 07:22 ET · Ratings

Earnings Call Summary | Neurocrine Biosciences(NBIX.US) Q1 2025 Earnings Conference

moomoo AIMay 5 21:50 ET · Conference Call